The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: A single centre egyptian study

Hepatitis Monthly

Volumn 13, Issue 5, 2013, Pages

  El Raziky, Maissa ^a   Fathalah, Waleed Fouad ^a   El Akel, Wafaa Ahmed ^a   Salama, Ahmed ^a   Esmat, Gamal ^a   Mabrouk, Mahassen ^a   Salama, Rabab Mamoun ^a   Khatab, Hany Mahmoud ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Chronic hepatitis C; Peginterferon alpha 2a; Peginterferon alpha 2b

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROTROPIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; VIRUS LOAD;

EID: 84881218751     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.10069     Document Type: Article

References (20)

1. Viral hepatitis: Report by the Secretariat. 2009; Available from: http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_15-en.pdf.
2. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepa-titis C in patients with drug dependence: time to change the rules? Addiction. 2004;99(9):1167-75.
3. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6(1):35-47.
4. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, et al. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg. 2001;64(3-4):147-53.
5. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epi-demiology of hepatitis C virus throughout egypt. J Infect Dis. 2000;182(3):698-707.
6. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylat-ed interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8(39):iii-iv, 1-125.
7. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther. 2004;9(4):491-7.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, manage-ment, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepa-titis C virus infection. N Engl J Med. 2002;347(13):975-82.
10. McHutchison J, Sulkowski M. Scientific rationale and study de-sign of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2008;15(7):475-81.
11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C.T.e METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
12. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
13. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus pa-tients. Hepatology. 2009;49(1):22-31.
14. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010;10(2):121-31.
15. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176-84.
16. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effec-tive than peginterferon alfa-2b plus ribavirin for treating chron-ic hepatitis C virus infection. Gastroenterology. 2010;138(1):116-22.
17. Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat. 2010;17(7):459-68.
18. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Sof-fredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108-15.
19. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavi-rin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004;22(4):257-65.
20. Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW. Changes in anti-viral effectiveness of interferon af-ter dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol. 2001;1:14.